Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.33 |
| ▸ | SLC25A5 | P05141 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6851434 | 0.89 | HTR3A (0.47) | HTR3AADRA2AADRA2BADRA2CSLC6A4 | |
| SCHEMBL13531389 | 0.80 | HTR3A (0.42) | HTR3AADRA2AADRA2BADRA2CSLC6A4 | |
| SCHEMBL13531413 | 0.80 | HTR3A (0.42) | HTR3AADRA2AADRA2BADRA2CSLC6A4 | |
| SCHEMBL3176454 | 0.78 | ADRA1A (0.42) | HTR3AADRA2AADRA2BADRA2CSLC6A4 | |
| SCHEMBL3176458 | 0.78 | ADRA1A (0.42) | HTR3AADRA2AADRA2BADRA2CSLC6A4 | |
| SCHEMBL6851100 | 0.77 | MEN1 (0.36) | HTR3AADRA2AADRA2BADRA2CSLC6A4 | |
| SCHEMBL7332677 | 0.77 | HTR3A (0.39) | HTR3AADRA2AADRA2BADRA2CSLC6A4 | |
| SCHEMBL3185643 | 0.77 | ADRA1A (0.40) | HTR3AADRA2AADRA2BADRA2CSLC6A4 | |
| Hydrochloric Acid SCHEMBL3184840 | 0.77 | ADRA1A (0.41) | HTR3AADRA2AADRA2BADRA2CSLC6A4 | |
| SCHEMBL3185647 | 0.77 | ADRA1A (0.40) | HTR3AADRA2AADRA2BADRA2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6756384-B2 | TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. | NOVO NORDISK A/S (DK) | 2004-06-29 | — | — | US | disclosed |
| US-20030135056-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2003-07-17 | — | — | US | disclosed |
| EP-1268484-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-6437147-B1 | FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM | NOVO NORDISK (DK) | 2002-08-20 | — | — | US | disclosed |
| US-20020058659-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2002-05-16 | — | — | US | disclosed |
| WO-2001068652-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135056-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | HTR3A 53/4885ADRA2A 155/4885ADRA2B 218/4885 |
| US-20020058659-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | HTR3A 53/4885ADRA2A 155/4885ADRA2B 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.